Aller au contenu principal
Fermer
  2. Aide
  2. Aide

Transgene reports business update and Q3 2021 financial position
information fournie par Boursorama CP 04/11/2021 à 17:45

- Data presented at ESMO in September provided clinical proof of concept for the intravenous administration of Transgene’s patented oncolytic virus (Invir.IO™ platform)—significantly expanding the market opportunity

- First data from two ongoing Phase I trials of the individualized cancer vaccine TG4050 (myvac® platform) will be communicated in the second half of November 2021

- €40.9 million in cash and cash equivalents as of September 30, 2021, further strengthened by the €17.4 million received in October 2021 from the partial sale of Tasly BioPharmaceuticals shares

- Financial visibility until the end of 2023

.../...

Valeurs associées

TRANSGENE
0,7440 EUR Euronext Paris -0,80%

0 commentaire

Signaler le commentaire

Fermer

A lire aussi

Mes listes

valeur

dernier

var.
Pétrole Brent
76,4 +0,66%
CAC 40
8 326,62 +0,90%
Or
4 123,96 +0,06%
2CRSI
31,8 -1,91%
EUR/USD SPOT
1,14579 +0,23%
Chargement...

Pages les plus populaires

L'offre BoursoBank